Adherence to disease-modifying therapy in multiple sclerosis: Part II.

Area of Science:

• Neurology
• Behavioral Science
• Rehabilitation Nursing

Background:

• Multiple sclerosis (MS) is a chronic, debilitating neurological disease with no cure.
• Injectable immunomodulating agents can reduce relapses and slow disease progression in MS.
• Patient acceptance and healthcare professional promotion are crucial for the effectiveness of disease-modifying agents in MS.

Purpose of the Study:

• To explore obstacles to treatment adherence in multiple sclerosis (MS).
• To propose the transtheoretical model of behavior change as a tool to improve patient acceptance and treatment goals in MS.
• To provide insights for nurses to encourage MS patients in initiating and continuing therapy.

Main Methods:

• This article is Part II of a two-part series, building upon Part I's description of MS treatment adherence problems.
• It proposes the application of the transtheoretical model of behavior change.
• The model emphasizes patient readiness for change and sensitivity to evolving patient conditions.

Main Results:

• Treatment adherence in MS is complex due to the disease's unpredictable course and potential treatment side effects.
• The transtheoretical model can be a valuable tool for enhancing patient acceptance and achieving therapeutic goals.
• Understanding patient readiness for change is fundamental for successful interventions.

Conclusions:

• The transtheoretical model of behavior change offers a structured approach to address challenges in MS treatment adherence.
• Nurses can utilize this model to better support patients in managing their condition and adhering to therapy.
• Tailoring interventions to the patient's stage of change is key to improving adherence and outcomes in multiple sclerosis.